Latest News | 'Cap on Trade Margin of 42 Non-scheduled Cancer Drugs by NPPA Led to Up to 90 Pc Reduction in MRP'

New Delhi, Aug 10 (PTI) Putting a cap on the trade margin of 42 select non-scheduled anti-cancer medicines by the National Pharmaceutical Pricing Authority (NPPA) resulted in reduction of up to 90 per cent in the maximum retail price of 526 brands of these drugs, Parliament was informed on Tuesday.

This was done under the 'Trade Margin Rationalisation' (TMR) approach, Minister of Chemicals and Fertilisers Mansukh Mandaviya said in a written reply to a question in the Lok Sabha.

Also Read | Samsung Galaxy S21 FE Reportedly Spotted on Official Instagram Account.

The NPPA has also brought 106 non-scheduled anti-diabetic and cardiovascular drugs under price control by invoking extraordinary powers in public interest, he added.

"The total annual savings on account of revision of ceiling prices of medicines under the National List of Essential Medicines (NLEM), price control of anti-diabetic and cardiovascular, fixation of ceiling price of stents, knee implants and capping of TMR on anti-cancer are estimated to the tune of Rs 12,500 crore," Mandaviya said.

Also Read | How To Get People's Attention as an Entrepreneur: The Jeremiah Evans Formula.

The NPPA monitors the ceiling price of the scheduled formulations to ensure that the MRP of such formulations are within the range of ceiling price. It also monitors non-scheduled formulations to ensure that their MRP does not increase by more than 10 percent during the preceding 12 months, he added. HRS hrs

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)